Buscar
Lantern Pharma Inc
LTRNAñadir a la lista de seguimiento
2.630USD
-0.020-0.75%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
33.56MCap. mercado
PérdidaP/E TTM
Más Datos de Lantern Pharma Inc Compañía
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Información de Lantern Pharma Inc
Símbolo de cotizaciónLTRN
Nombre de la empresaLantern Pharma Inc
Fecha de salida a bolsaJun 11, 2020
Director ejecutivoSharma (Panna L)
Número de empleados24
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 11
Dirección1920 Mckinney Avenue
CiudadDALLAS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal75201
Teléfono19722771136
Sitio Webhttps://www.lanternpharma.com/
Símbolo de cotizaciónLTRN
Fecha de salida a bolsaJun 11, 2020
Director ejecutivoSharma (Panna L)
Ejecutivos de Lantern Pharma Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Vijay Chandru, Ph.D.
Dr. Vijay Chandru, Ph.D.
Independent Director
Independent Director
--
--
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lee T. Schalop, M.D.
Dr. Lee T. Schalop, M.D.
Director
Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Vijay Chandru, Ph.D.
Dr. Vijay Chandru, Ph.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Lantern Pharma Inc?
Los cinco principales accionistas de Lantern Pharma Inc son: Mr. Panna L. Sharma
¿Cuántas instituciones poseen acciones de Lantern Pharma Inc (LTRN)?
A fecha de 2026Q1, 78 instituciones poseen acciones de Lantern Pharma Inc, con un valor de mercado combinado de aproximadamente 2.65M, lo que representa el 23.45% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 119203.00.